FAM22E Inhibitors
FAM22E inhibitors are a class of chemical compounds that target the FAM22E protein, a biological entity whose functions are intricately linked to specific cellular processes. These inhibitors work by disturbing the normal activity of FAM22E within its native pathways. The inhibition mechanism may involve direct binding to the FAM22E protein, thereby altering its conformation and preventing it from interacting with its natural substrates or partners within the cell. Alternatively, FAM22E inhibitors could function by interfering with upstream or downstream signaling molecules that regulate the activity of FAM22E. By doing so, they can indirectly reduce the protein's functional output. The exact molecular interaction varies depending on the inhibitor in question, but the underlying theme revolves around hindering the protein's ability to participate in its normal biological roles, such as signal transduction, gene expression regulation, or other cellular pathways where FAM22E is a critical player.
In more detail, the specificity of FAM22E inhibitors is vital to their function, as indiscriminate inhibition could disrupt multiple cellular pathways and lead to unintended consequences. Therefore, the design of these inhibitors often involves a comprehensive understanding of the protein's structure and the precise molecular cascade in which it is involved. Inhibitors may target the active site of FAM22E, competing with natural substrates, or bind to allosteric sites that result in a functional change in protein activity. Others may interact with the regulatory regions of the gene that encodes for FAM22E, leading to a decrease in its expression. The biochemical pathways that FAM22E participates in are complex, and the inhibitors must be crafted to ensure that they only affect the intended target without altering the function of other proteins that may have similar structures or mechanisms. This precision ensures the high specificity of FAM22E inhibitors in their action, enabling them to serve as useful tools in research settings where dissecting the role of FAM22E is necessary.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is upstream of many signaling pathways that can include the functional regulation of FAM22E. By inhibiting EGFR, Erlotinib reduces the activity of downstream signaling pathways, potentially leading to decreased activity of FAM22E if it is regulated by such pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. The mTOR pathway is involved in cell growth, proliferation, and survival. Inhibition of mTOR by Rapamycin could lead to reduced protein synthesis and potentially lower expression or activity of FAM22E if it is involved in these cellular processes. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple tyrosine protein kinases, such as VEGFR and PDGFR, which are involved in cell signaling related to growth and angiogenesis. If FAM22E plays a role in these pathways, Sorafenib could dampen its functional activity by inhibiting these pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. It changes the chromatin structure and can affect gene expression. If FAM22E expression is regulated by histone acetylation, Trichostatin A could decrease its expression and thus its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. The PI3K/Akt pathway is crucial for many cellular functions including metabolism, growth, and survival. If FAM22E functions are regulated via this pathway, LY294002 could reduce its activity by inhibiting PI3K. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor which affects the cell cycle. If FAM22E is involved in cell cycle regulation, inhibition of CDK4/6 could lead to reduced activity of FAM22E. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide modulates the expression of multiple cytokines. If FAM22E is regulated by cytokine signaling, Thalidomide could indirectly decrease its activity by altering cytokine environments. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor, specifically targeting BCR-ABL, c-Kit, and PDGFR. If FAM22E activity is connected to signaling pathways involving these kinases, Imatinib could lead to a decrease in FAM22E activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting the proteasome, it affects protein turnover. If FAM22E is subject to proteasomal degradation, Bortezomib could alter its functional levels and activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, part of the MAPK/ERK pathway. If FAM22E is regulated by the MAPK/ERK signaling pathway, the inhibition of this pathway by U0126 could result in decreased FAM22E activity. | ||||||